WhisperSom™ Announces Common Stock Offering

For the Manufacturing of Innovative New Sleep Apnea Treatment

The Company's noninvasive neuromodulation technology is considered a potential breakthrough for diagnosing and treating sleep apnea and snoring

The solution resembles a precision health tracker, which could significantly increase adoption and adherence to treatment

1,550 Units of the Company's shares of common voting stock are being offered to accredited and institutional investors

ANNAPOLIS, Md., Jan. 10, 2024 /PRNewswire/ -- WhisperSom™ Corporation, a medical device and informatics company specializing in the diagnosis and treatment of sleep apnea and snoring, today announced the offering of 1,550 Units of the Company's common stock. The offering is limited to accredited and institutional investors and the Company's stock is listed on a blockchain platform for privately held securities.

Read more here